)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Aktis Oncology
Aktis Oncology (AKTS) investor relations material
Aktis Oncology Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary30 Mar, 2026
Executive summary
FDA cleared IND applications for AKY-2519, enabling a Phase 1b clinical trial in mid-2026 targeting B7-H3 in solid tumors.
Lead program AKY-1189, targeting Nectin-4, is enrolling in a Phase 1b trial and received FDA Fast Track designation in February 2026.
IPO in January 2026 raised $365.4M gross, supporting expansion and clinical development.
Financial highlights
Cash, cash equivalents, and marketable securities were $226.8M as of December 31, 2025; pro forma as adjusted cash post-IPO is $562.1M.
Collaboration revenue rose to $6.5M for 2025 from $1.5M in 2024, mainly from the Eli Lilly partnership.
R&D expenses increased to $67.5M in 2025 from $41.0M in 2024, driven by higher headcount and program advancement.
G&A expenses were $13.7M in 2025, up from $12.6M in 2024, reflecting business growth.
Net loss widened to $63.7M in 2025 from $44.0M in 2024, primarily due to increased R&D spending.
Outlook and guidance
Preliminary data from Part 1 of the AKY-1189 Phase 1b trial expected in Q1 2027.
Results from AKY-2519 imaging and dosimetry assessment expected mid-2026; Phase 1b trial to start mid-2026.
Early pipeline programs aim for development candidate nomination and IND-enabling activities in Q1 2027.
In-house GMP facility expected operational in H2 2026 to support clinical supply.
Pro forma cash position expected to fund operations into 2029.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aktis Oncology
- Innovative radiopharmaceutical platform advances with strong pipeline, partnerships, and cash runway.AKTS
Leerink Global Healthcare Conference 20269 Mar 2026 - First-in-class radiopharmaceuticals advance toward major milestones in a growing market.AKTSTD Cowen 46th Annual Health Care Conference3 Mar 2026
- IPO seeks $274.5M to fund radiopharmaceutical cancer pipeline, with Eli Lilly as key partner.AKTSRegistration Filing7 Jan 2026
- IPO seeks $181.7M to advance radiopharmaceutical pipeline, with Eli Lilly partnership and strong cash.AKTSRegistration Filing5 Jan 2026
- Developing next-gen radiopharmaceuticals for solid tumors, leveraging strong cash and Eli Lilly partnership.AKTSRegistration Filing29 Dec 2025
Next Aktis Oncology earnings date
Q1 202615 May, 2026
Aktis Oncology
Next Aktis Oncology earnings date
Q1 202615 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage